Mercuri E, et al. - The efficacy of nusinersen, an antisense oligonucleotide drug), was compared to sham control for the treatment of spinal muscular atrophy (SMA) in children. Individuals receiving nusinersen exhibited notable and clinically significant improvement in motor function than the control group among children with later-onset SMA.